Eskazine - General Information
A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. [PubChem]
Pharmacology of Eskazine
Eskazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Eskazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.
Eskazine for patients
No information provided.
A known hypersensitivity to phenothiazines, comatose or greatly depressed states due to central nervous system depressants and, in cases of existing blood dyscrasias, bone marrow depression and pre-existing liver damage.
Additional information about Eskazine
Eskazine Indication: For the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.
Mechanism Of Action: Eskazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Trifluoperazine
Synonyms: Not Available
Drug Category: Antipsychotics; Antiemetics; Phenothiazines
Drug Type: Small Molecule; Approved
Absorption: Not Available
Toxicity (Overdose): Symptoms of overdose include agitation, coma, convulsions, difficulty breathing, difficulty swallowing, dry mouth, extreme sleepiness, fever, intestinal blockage, irregular heart rate, low blood pressure, and restlessness.
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: Not Available
Dosage Forms of Eskazine: Tablet Oral
Chemical IUPAC Name: 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine
Chemical Formula: C21H24F3N3S
Trifluoperazine on Wikipedia: https://en.wikipedia.org/wiki/Trifluoperazine
Organisms Affected: Humans and other mammals